Volume 6 Supplement 1
Efficacy of ventricular access devices in the treatment of neonatal intraventricular haemorrhage
© Shooman et al; licensee BioMed Central Ltd. 2009
Published: 3 February 2009
Post Haemorrhagic Hydrocephalus (PHH) secondary to Neonatal Intraventricular Haemorrhage (IVH) is the commonest cause of infantile hydrocephalus. The presence of ventricular blood, underdeveloped immune systems and thin, friable skin preclude shunting as a primary intervention. Studies show that serial lumbar punctures, medical management and ventricular taps have no discernible effect on outcome. This study attempts to more clearly elucidate the role and efficacy of ventricular access devices (VAD) in the treatment of PHH. The aims were to determine the complication rate, the use of the VAD and the number of patients with VAD who later required shunting.
Materials and methods
29 Neonates were identified from the Leeds General Infirmary (LGI) database from 1999 to 2005 who underwent VAD insertion. A retrospective review of the notes from the LGI and the referring hospitals during the period of VAD insertion was undertaken.
Complication rate was 12% with two wound breakdowns and one cardiorespiratory arrest. 62% required a shunt, 71% of whom had a birth weight of less than 1 Kg and 78% were born at less than 27 weeks. The shunted patients had their VAD accessed far more frequently than the non-shunted group. There was an average of 10.4 taps per shunted patient. 24/29 utilised the VAD regularly, but there was poor documentation of opening and closing pressures, ventricular indices and head circumference both pre and post tapping. 10/29 utilised VAD but did not require shunting, it is equivocal whether maturation would have taken place regardless of the VAD. There is a direct association between frequent use of the VAD and shunting suggesting a useful treatment tool with minimal complications.
The low complication rate associated with VAD suggests that they should be the intervention of choice in neonates with PHH. The role of the VAD is to 'buy time' allowing the patient to mature to a sufficient size prior to shunt insertion and to distinguish the group of patients with progressive PHH from those that will not require shunt placement. It is additionally recommended that more vigilance over documentation of VAD utilisation needs to be adhered to by the neonatal team.
This article is published under license to BioMed Central Ltd.